Therefore, the expanded RAS mutation analysis needs to be known before anti-EGFR treatment in mCRC, performed on tumor DNA from any location, as long as the performing lab complies with nationally or internationally qualified quality assurance programs (I, A). The gene discussed is EGFR; the disease is neoplasm.